IT1226861B - Vaccini contenenti antigeni tumorali e coadiuvanti e relativo procedimento di preparazione - Google Patents

Vaccini contenenti antigeni tumorali e coadiuvanti e relativo procedimento di preparazione

Info

Publication number
IT1226861B
IT1226861B IT8822145A IT2214588A IT1226861B IT 1226861 B IT1226861 B IT 1226861B IT 8822145 A IT8822145 A IT 8822145A IT 2214588 A IT2214588 A IT 2214588A IT 1226861 B IT1226861 B IT 1226861B
Authority
IT
Italy
Prior art keywords
adjuvants
tumor antigens
preparation procedure
vaccines containing
containing tumor
Prior art date
Application number
IT8822145A
Other languages
English (en)
Italian (it)
Other versions
IT8822145A0 (it
Inventor
John Leonard Cantrell
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of IT8822145A0 publication Critical patent/IT8822145A0/it
Application granted granted Critical
Publication of IT1226861B publication Critical patent/IT1226861B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IT8822145A 1987-09-30 1988-09-30 Vaccini contenenti antigeni tumorali e coadiuvanti e relativo procedimento di preparazione IT1226861B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/102,909 US4877611A (en) 1986-04-15 1987-09-30 Vaccine containing tumor antigens and adjuvants

Publications (2)

Publication Number Publication Date
IT8822145A0 IT8822145A0 (it) 1988-09-30
IT1226861B true IT1226861B (it) 1991-02-19

Family

ID=22292343

Family Applications (1)

Application Number Title Priority Date Filing Date
IT8822145A IT1226861B (it) 1987-09-30 1988-09-30 Vaccini contenenti antigeni tumorali e coadiuvanti e relativo procedimento di preparazione

Country Status (10)

Country Link
US (1) US4877611A (cg-RX-API-DMAC10.html)
JP (1) JPH01163130A (cg-RX-API-DMAC10.html)
BE (1) BE1001634A4 (cg-RX-API-DMAC10.html)
CA (1) CA1333152C (cg-RX-API-DMAC10.html)
CH (1) CH678492A5 (cg-RX-API-DMAC10.html)
DE (1) DE3833319A1 (cg-RX-API-DMAC10.html)
FR (1) FR2620941B1 (cg-RX-API-DMAC10.html)
GB (1) GB2210557B (cg-RX-API-DMAC10.html)
IT (1) IT1226861B (cg-RX-API-DMAC10.html)
NL (1) NL8802393A (cg-RX-API-DMAC10.html)

Families Citing this family (226)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5212085A (en) * 1987-12-09 1993-05-18 The General Hospital Corporation Sf-25 colon adenocarcinoma antigen, and antibodies with recognize this antigen
DE3854999T2 (de) * 1987-12-09 1996-11-14 Gen Hospital Corp An karzinoma assoziierte antigene und antikörper, die diese antigene erkennen
DE3922444A1 (de) * 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
US6093406A (en) * 1988-06-02 2000-07-25 The United States Of America As Represented By The Secretary Of The Army Vaccine for induction of immunity to malaria
JPH04501663A (ja) * 1988-09-23 1992-03-26 ユニバーシティ・オブ・サザン・カリフォルニア 黒色腫用免疫療法ワクチン
US4963364A (en) * 1989-04-10 1990-10-16 Fox Sidney W Microencapsulated antitumor agent
ATE155813T1 (de) * 1989-05-19 1997-08-15 Genentech Inc Her2 extrazellulare domäne
US6177083B1 (en) * 1990-07-26 2001-01-23 Evax Technologies Gmbh Process for the production of vaccines and their use
US5413993A (en) * 1991-08-20 1995-05-09 Gen-Ichiro Soma Method for the treatment of narcotic withdrawal symptoms in animals using lipopolysaccharides
CA2049548C (en) * 1990-08-20 2002-07-02 Kiyoshi Yoshimura Lps-producing bacteria, lpss, and lps-containing medicines and veterinary medicines
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
AU660325B2 (en) * 1991-10-11 1995-06-22 Eisai Co. Ltd. Anti-endotoxin compounds and related molecules and methods
US5530113A (en) * 1991-10-11 1996-06-25 Eisai Co., Ltd. Anti-endotoxin compounds
UA40597C2 (uk) * 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
AU6409894A (en) * 1993-03-16 1994-10-11 Samuel Bogoch Recognin vaccines
CN1087176C (zh) * 1993-03-23 2002-07-10 史密斯克莱·比奇曼生物公司 含有3－o脱酰基单磷酰脂a的疫苗制剂
DE69434475T2 (de) * 1993-08-11 2006-05-18 Jenner Technologies, Tiburon Impfstoff gegen prostatakrebs
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
USD365131S (en) 1994-05-25 1995-12-12 Royal Grip, Inc. Golf club grip
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US6117432A (en) * 1995-04-20 2000-09-12 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
FR2733151B1 (fr) * 1995-04-20 1997-05-23 Seppic Sa Composition therapeutique comprenant un antigene ou un generateur in vivo d'un compose comprenant une sequence d'acides amines
US6689370B1 (en) 1995-04-20 2004-02-10 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6406689B1 (en) 1995-10-03 2002-06-18 Frank W. Falkenberg Compositions and methods for treatment of tumors and metastatic diseases
US6303584B1 (en) * 1996-11-20 2001-10-16 The University Of Montana Water soluble lipidated arabinogalactan
IL134371A0 (en) 1997-08-05 2001-04-30 Bioniche Life Sciences Inc Composition and method for regulating cell proliferation and cell death
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6280742B1 (en) 1998-06-17 2001-08-28 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
JP4447779B2 (ja) * 1998-07-16 2010-04-07 市郎 東 細菌の菌体成分を有効成分とする癌免疫療法用製剤
IL141044A0 (en) 1998-08-07 2002-02-10 Univ Washington Innunological herpes simplex virus antigens and methods for use thereof
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20010033839A1 (en) * 1999-10-04 2001-10-25 Emilio Barbera-Guillem Vaccine and immunotherapy for solid nonlymphoid tumor and related immune dysregulation
EP1144642B1 (en) 1998-12-08 2010-05-26 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
MXPA01009962A (es) 1999-04-02 2002-08-20 Corixa Corp Compuestos y metodos para terapia y diagnostico de cancer de pulmon.
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
CA2386841A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
RU2152800C1 (ru) * 1999-12-08 2000-07-20 Зыбин Дмитрий Владимирович Способ культивирования и модификации гетерогенных клеток млекопитающих
AU785212B2 (en) * 1999-12-13 2006-11-09 Bioniche Life Sciences Inc. Therapeutically useful synthetic oligonucleotides
NZ520312A (en) * 1999-12-28 2003-08-29 Bioniche Life Sciences Inc Hyaluronic acid in the treatment of cancer
EP1265915B1 (en) 2000-02-23 2010-11-10 GlaxoSmithKline Biologicals s.a. Novel compounds
WO2001062893A2 (en) * 2000-02-25 2001-08-30 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
EP2192128A3 (en) 2000-04-21 2010-09-22 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20030139356A1 (en) * 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
JP5004261B2 (ja) 2000-05-19 2012-08-22 コリクサ コーポレイション 単糖類及び二糖類に基づく化合物を用いた感染症及び他の疾患の予防的並びに治療的な処置
ATE442866T1 (de) 2000-06-20 2009-10-15 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
EP1319069B1 (en) 2000-06-28 2008-05-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
RU2192884C2 (ru) * 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
CU22999A1 (es) * 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
DE10132502A1 (de) * 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
WO2003005952A2 (en) 2001-07-10 2003-01-23 Corixa Corporation Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
WO2003025003A2 (en) 2001-09-20 2003-03-27 Glaxo Group Limited Hiv-gag codon-optimised dna vaccines
WO2003028758A1 (en) * 2001-09-28 2003-04-10 Haruo Sugiyama Novel method of inducing antigen-specific t cells
US20030215460A1 (en) * 2002-05-07 2003-11-20 Schall Thomas J. Methods and compositions for inducing an immune response
US20030157101A1 (en) * 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides
ES2405790T3 (es) 2001-12-17 2013-06-03 Corixa Corporation Composiciones y métodos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
US7026465B2 (en) * 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
WO2003073827A2 (en) * 2002-02-28 2003-09-12 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
DE60324678D1 (de) 2002-07-18 2008-12-24 Univ Washington N t-lymphozyten und damit identifizierte hsv-antigene
WO2004012751A1 (ja) * 2002-08-02 2004-02-12 Sumitomo Pharmaceuticals Company, Limited 細菌細胞壁骨格成分製剤
EP3254673A1 (en) * 2002-11-13 2017-12-13 The UAB Research Foundation Synthetic single domain polypeptides mimicking apolipoprotein e and methods of use
CA2512108C (en) 2003-01-06 2013-04-02 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
WO2005071058A2 (en) * 2004-01-27 2005-08-04 Compugen Ltd. Methods and systems for annotating biomolecular sequences
WO2005102369A1 (ja) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. 細菌細胞壁骨格成分を含有する製剤
WO2006031264A2 (en) 2004-05-25 2006-03-23 Oregon Health And Science University Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
ATE491467T1 (de) 2004-05-28 2011-01-15 Glaxosmithkline Biolog Sa Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
EP2808384B1 (en) 2004-10-08 2017-12-06 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Modulation of replicative fitness by using less frequently used synonymous codons
WO2006065549A2 (en) 2004-12-03 2006-06-22 Medical University Of Ohio Attenuated vaccine useful for immunizations against coccidioides spp. infections
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
US20090022755A1 (en) 2005-03-31 2009-01-22 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
PL1877426T3 (pl) 2005-04-29 2012-10-31 Glaxosmithkline Biologicals Sa Sposób profilaktyki lub leczenia zakażenia M. tuberculosis
WO2007015783A2 (en) * 2005-07-22 2007-02-08 Research Development Foundation Attenuated strains of flaviviruses , and uses thereof
CA2625406C (en) 2005-10-18 2016-08-09 Novavax, Inc. Functional influenza virus like particles (vlps)
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP1981905B1 (en) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
US8153116B2 (en) 2006-07-11 2012-04-10 University Of Connecticut Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
US8128921B2 (en) * 2006-07-11 2012-03-06 University Of Connecticut Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
PT2484375T (pt) 2006-09-26 2018-07-09 Infectious Disease Res Inst Composição para vacina contendo adjuvante sintético
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
JP5578390B2 (ja) * 2007-03-05 2014-08-27 株式会社 Ｍｂｒ 細菌細胞壁骨格成分の製造方法
US8486414B2 (en) 2007-04-04 2013-07-16 Infectious Disease Research Institute Immunogenic compositions comprising Mycobacterium tuberculosis polypeptides and fusions thereof
TW200908994A (en) * 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
HUE025702T2 (en) 2007-07-19 2016-04-28 Novavax Inc Avian Flu Chimeric VLPs
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
EP2195340A4 (en) 2007-08-28 2011-05-11 Uab Research Foundation SYNTHETIC APOLIPOPROTEIN E-IMITATING POLYPEPTIDES AND METHOD OF USE
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
US20090215908A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Toll like receptor (tlr) signaling antagonist
NZ599777A (en) 2007-11-07 2013-09-27 Celldex Therapeutics Inc Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
EP4670734A2 (en) 2007-12-24 2025-12-31 GlaxoSmithKline Biologicals S.A. RECOMBINANT RSV ANTIGENS
WO2009095925A2 (en) * 2008-01-31 2009-08-06 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
ES2566750T3 (es) 2008-04-16 2016-04-15 The Johns Hopkins University Método para determinar el riesgo de recidiva de cáncer de próstata
CA2731194A1 (en) * 2008-07-18 2010-01-21 Id Biomedical Corporation Of Quebec Chimeric respiratory syncytial virus polypeptide antigens
DK2352756T3 (da) 2008-11-24 2012-12-03 Helmholtz Zentrum Muenchen Højaffin T-cellereceptor og anvendelse af denne
AU2009320287B2 (en) 2008-11-26 2015-10-08 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus like particle compositions and methods of use
PL2370099T3 (pl) 2008-12-09 2016-10-31 Zmodyfikowane białka F RSV i sposoby ich zastosowania
SG2014014385A (en) 2009-02-17 2014-04-28 Glaxosmithkline Biolog Sa Inactivated dengue virus vaccine with aluminium-free adjuvant
US8722064B2 (en) 2009-06-05 2014-05-13 Infectious Disease Research Institute Synthetic glucopyranosyl lipid adjuvants
PT2445526T (pt) 2009-06-24 2016-08-16 Glaxosmithkline Biologicals Sa Antigénios de rsv recombinantes
EP2445527A2 (en) 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccine
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
EP2451950B9 (en) 2009-07-06 2016-11-23 Variation Biotechnologies Inc. Methods for preparing vesicles and formulations produced therefrom
EP2453918B1 (en) 2009-07-15 2015-12-16 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
KR101125764B1 (ko) 2010-01-27 2012-03-27 백태현 항산균 세포벽골격을 이용한 백신매개체 및 그에 의한 백신의 제조 방법
EA024701B1 (ru) 2010-04-13 2016-10-31 Селлдекс Терапьютикс Инк. Антитела, связывающие cd27 человека, и их применение
JP5933538B2 (ja) * 2010-07-02 2016-06-08 インターベット インターナショナル ベー． フェー． エーリキア・カニスに対するワクチンおよび関連する方法
JP6119030B2 (ja) 2010-07-06 2017-04-26 ヴァリエーション バイオテクノロジーズ インコーポレイテッド インフルエンザを治療するための組成物及び方法
ES2635014T3 (es) 2010-10-15 2017-10-02 Glaxosmithkline Biologicals S.A. Antígeno gB del citomegalovirus
US20130345079A1 (en) 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
JP6158088B2 (ja) 2010-11-05 2017-07-05 ノババックス，インコーポレイテッド 狂犬病糖タンパク質ウイルス様粒子（ｖｌｐ）
US20120114688A1 (en) 2010-11-08 2012-05-10 Infectious Disease Research Institute Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
HRP20160362T1 (hr) 2010-12-14 2016-05-06 Glaxosmithkline Biologicals S.A. Antigeni pripravak protiv bakterija iz roda mycobacterium
BR112013017939B1 (pt) 2011-01-13 2022-11-16 Variation Biotechnologies Inc Composição imunogênica liofilizada termoestável, uso e método para preparação da mesma
US9487563B2 (en) 2011-01-31 2016-11-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-like particles and methods of use
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
US20140248314A1 (en) 2011-05-13 2014-09-04 Novartis Ag Pre-fusion rsv f antigens
CA2837651A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
GB201119999D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
GB201120000D0 (en) 2011-11-20 2012-01-04 Glaxosmithkline Biolog Sa Vaccine
CA2894442C (en) 2012-01-12 2020-01-21 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
CA2894467A1 (en) 2012-01-27 2013-08-01 Variation Biotechnologies Inc. Methods for preparing thermostable compositions comprising a lipid component and thermolabile therapeutic agents
CN104203270A (zh) 2012-03-18 2014-12-10 葛兰素史密丝克莱恩生物有限公司 针对人乳头状瘤病毒的接种方法
SG11201407586WA (en) 2012-05-16 2014-12-30 Immune Design Corp Vaccines for hsv-2
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
ES2969734T3 (es) 2012-08-03 2024-05-22 Access To Advanced Health Inst Composiciones y métodos para tratar una infección activa por Mycobacterium tuberculosis
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
HUE061273T2 (hu) 2012-12-05 2023-06-28 Glaxosmithkline Biologicals Sa Immunogén készítmény
EP2970398B1 (en) 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
AU2014236135A1 (en) 2013-03-14 2015-09-10 Thomas Jefferson University Androgen receptor down-regulating agents and uses thereof
BE1022174B1 (fr) 2013-03-15 2016-02-24 Glaxosmithkline Biologicals S.A. Vaccin
WO2014160987A2 (en) 2013-03-28 2014-10-02 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
HK1214510A1 (zh) 2013-04-18 2016-07-29 Immune Design Corp. 用於癌症治疗的gla单一疗法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
ES3020582T3 (en) 2013-07-26 2025-05-23 Inst Nat Sante Rech Med Methods and pharmaceutical compositions for the treatment of bacterial infections
CN105555304A (zh) 2013-08-05 2016-05-04 葛兰素史密丝克莱恩生物有限公司 联合免疫原性组合物
EP3033088A4 (en) 2013-08-12 2017-03-08 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
SG11201601423SA (en) 2013-09-19 2016-04-28 Novavax Inc Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
EP3146081B1 (en) 2014-05-19 2020-10-28 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
EP3888676A1 (en) 2014-06-13 2021-10-06 GlaxoSmithKline Biologicals S.A. Immunogenic combinations
CN106536544B (zh) 2014-06-25 2020-04-07 葛兰素史密丝克莱恩生物有限公司 艰难梭菌免疫原性组合物
CA2954475C (en) 2014-07-31 2023-05-16 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
CA2959336A1 (en) 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
WO2016097865A1 (en) 2014-12-19 2016-06-23 Regenesance B.V. Antibodies that bind human c6 and uses thereof
CN107406857B (zh) 2015-01-09 2021-06-29 埃图比克斯公司 用于联合免疫治疗的方法和组合物
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
US10682314B2 (en) 2015-05-26 2020-06-16 Ohio State Innovation Foundation Nanoparticle based vaccine strategy against swine influenza virus
US20170226171A1 (en) * 2016-02-09 2017-08-10 Vaccinogen, Inc. Adenocarcinoma antigenic determinants and methods
JP2019511483A (ja) 2016-03-02 2019-04-25 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 免疫療法のためのｓｔｉｎｇ活性化ナノワクチン
SG11201808821WA (en) 2016-04-18 2018-11-29 Celldex Therapeutics Inc Agonistic antibodies that bind human cd40 and uses thereof
CA3024313A1 (en) 2016-05-21 2017-11-30 Infectious Disease Research Institute Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections
CN109890408A (zh) 2016-05-27 2019-06-14 埃特彼塞斯公司 新表位疫苗组合物及其使用方法
BR112019004913B1 (pt) 2016-09-16 2022-07-12 Infectious Disease Research Institute Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
GB201616904D0 (en) 2016-10-05 2016-11-16 Glaxosmithkline Biologicals Sa Vaccine
BR112019011286A2 (pt) 2016-12-07 2019-10-15 Glaxosmithkline Biologicals S.A. métodos para produzir uma composição de lipossoma, para preparar uma composição de vacina e para preparar um kit de vacina.
EP3554538A2 (en) 2016-12-16 2019-10-23 Institute for Research in Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
EP3612562A2 (en) 2017-04-19 2020-02-26 Institute for Research in Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
WO2018198085A1 (en) 2017-04-28 2018-11-01 Glaxosmithkline Biologicals Sa Vaccination
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
CN111032080A (zh) 2017-05-30 2020-04-17 葛兰素史密丝克莱恩生物有限公司 用于制造佐剂的新型方法
MX2019015076A (es) 2017-06-15 2020-08-03 Infectious Disease Res Inst Portadores lípidos nanoestructurados y emulsiones estables y usos de los mismos.
EP3638301A1 (en) 2017-06-16 2020-04-22 GlaxoSmithKline Biologicals S.A. Method of treatment
WO2019035963A1 (en) 2017-08-16 2019-02-21 Ohio State Innovation Foundation NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
CN111836639A (zh) 2018-01-26 2020-10-27 河谷细胞有限公司 用于联合癌症疫苗和免疫辅助疗法的组合物和方法
US20190275134A1 (en) 2018-03-12 2019-09-12 Janssen Pharmaceuticals, Inc Vaccines against urinary tract infections
JP7466459B2 (ja) 2018-04-17 2024-04-12 セルデックス セラピューティクス インコーポレイテッド 抗ｃｄ２７および抗ｐｄ－ｌ１抗体ならびに二重特異性構築物
EP3581201A1 (en) 2018-06-15 2019-12-18 GlaxoSmithKline Biologicals S.A. Escherichia coli o157:h7 proteins and uses thereof
EA202190136A1 (ru) 2018-07-31 2021-05-14 Глаксосмитклайн Байолоджикалс Са Способ очистки антигена
JP7320601B2 (ja) 2018-09-11 2023-08-03 上▲海▼市公共▲衛▼生▲臨▼床中心 広域スペクトルな抗インフルエンザワクチン免疫原及びその使用
EP3921039A1 (en) * 2019-02-08 2021-12-15 University of Florida Research Foundation, Inc. A monophosphoryl lipid-a liposome based cancer vaccine
EP3980044A1 (en) 2019-06-05 2022-04-13 GlaxoSmithKline Biologicals SA Saponin purification
WO2021014385A1 (en) 2019-07-24 2021-01-28 Glaxosmithkline Biologicals Sa Modified human cytomegalovirus proteins
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
BR112022004228A2 (pt) 2019-09-09 2022-05-31 Glaxosmithkline Biologicals Sa Composições imunoterapêuticas
CN115151559A (zh) 2019-10-02 2022-10-04 扬森疫苗与预防公司 葡萄球菌肽和使用方法
US20230045642A1 (en) 2019-12-19 2023-02-09 Glaxosmithkline Biologicals Sa S. aureus antigens and compositions thereof
BR112022013720A2 (pt) 2020-01-16 2022-10-11 Janssen Pharmaceuticals Inc Mutante fimh, composições com o mesmo e seu uso
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US11376320B2 (en) 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2
WO2021214766A1 (en) 2020-04-21 2021-10-28 Yeda Research And Development Co. Ltd. Methods of diagnosing viral infections and vaccines thereto
EP4146378A1 (en) 2020-05-05 2023-03-15 GlaxoSmithKline Biologicals S.A. Microfluidic mixing device and methods of use
WO2021245025A1 (en) 2020-06-01 2021-12-09 Loop Diagnostics, S.L. Method and kit for the early detection of sepsis
US20230293659A1 (en) 2020-08-03 2023-09-21 Glaxosmithkline Biologicals Sa Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositions thereof
AU2021337493A1 (en) 2020-09-04 2023-05-18 Access To Advanced Health Institute Co-lyophilized rna and nanostructured lipid carrier
WO2022117595A2 (en) 2020-12-02 2022-06-09 Glaxosmithkline Biologicals Sa Novel antigens
US20240026407A1 (en) 2020-12-09 2024-01-25 Glaxosmithkline Biologicals Sa Modification of saponins
EP4267750A2 (en) 2020-12-24 2023-11-01 Plant Bioscience Limited Methods and enzymes for producing quillaic acid derivatives
MX2023008251A (es) 2021-01-12 2023-07-26 Janssen Pharmaceuticals Inc Mutantes de fimh, composiciones con estos y uso de estos.
MX2023009456A (es) 2021-02-11 2023-08-28 Glaxosmithkline Biologicals Sa Preparacion de la vacuna contra el vph.
CN117222427A (zh) 2021-04-01 2023-12-12 杨森制药公司 大肠杆菌o18生物缀合物的生产
CN117545773A (zh) 2021-04-09 2024-02-09 塞德斯医疗公司 抗ilt4的抗体、双特异性抗ilt4/pd-l1抗体及其用途
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
EP4469078A1 (en) 2022-01-28 2024-12-04 GlaxoSmithKline Biologicals S.A. Modified human cytomegalovirus proteins
EP4499817A1 (en) 2022-03-25 2025-02-05 Plant Bioscience Limited Biosynthesis
CN119403935A (zh) 2022-06-15 2025-02-07 葛兰素史克生物有限公司 皂苷的酶促修饰
GB202209588D0 (en) 2022-06-29 2022-08-10 Plant Bioscience Ltd Methods and compositions
WO2024052882A1 (en) 2022-09-09 2024-03-14 Access To Advanced Health Institute Immunogenic vaccine composition incorporating a saponin
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition
KR20250167153A (ko) 2023-03-03 2025-11-28 셀덱스 쎄라퓨틱스, 인크. 항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2160326B1 (cg-RX-API-DMAC10.html) * 1971-11-19 1975-02-07 Anvar
US4338334A (en) * 1977-12-29 1982-07-06 Merck & Co., Inc. 1-[4-(4-Sulfanilyl)phenyl] urea and derivatives in compositions and methods of treating rheumatoid arthritis and immune complex diseases
US4307229A (en) * 1979-11-07 1981-12-22 Avraham Liav 6,6'-Diesters of trehalose and process for the synthesis thereof
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4505903A (en) * 1982-06-30 1985-03-19 Ribi Immunochem Research, Inc. Pyridine soluble extract of a microorganism
US4606918A (en) * 1983-08-22 1986-08-19 Syntex (U.S.A.) Inc. Polyoxypropylene-polyoxyethylene block polymer based adjuvants
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use

Also Published As

Publication number Publication date
CA1333152C (en) 1994-11-22
FR2620941B1 (fr) 1990-08-10
IT8822145A0 (it) 1988-09-30
JPH0575731B2 (cg-RX-API-DMAC10.html) 1993-10-21
BE1001634A4 (fr) 1990-01-02
FR2620941A1 (fr) 1989-03-31
GB2210557A (en) 1989-06-14
GB2210557B (en) 1991-11-13
DE3833319C2 (cg-RX-API-DMAC10.html) 1992-06-11
GB8822749D0 (en) 1988-11-02
US4877611A (en) 1989-10-31
CH678492A5 (cg-RX-API-DMAC10.html) 1991-09-30
NL8802393A (nl) 1989-04-17
DE3833319A1 (de) 1989-04-13
JPH01163130A (ja) 1989-06-27

Similar Documents

Publication Publication Date Title
IT1226861B (it) Vaccini contenenti antigeni tumorali e coadiuvanti e relativo procedimento di preparazione
FR2629717B1 (fr) Preparation de vaccin
FR2598622B1 (fr) Adjuvants immunologiques pour vaccins polysaccharidiques
NO944475D0 (no) Kombinerte vaksiner omfattende Hepatit B overflateantigen og andre antigener
IT1205820B (it) Adiuvante immunologico per vaccini polisaccaridici
FI950405L (fi) Heikosti immunogeenisten antigeenien ja synteettisten peptidikantajien konjugaatit sekä niitä sisältävät rokotteet
DK189788D0 (da) Vaccine
NL990018I1 (nl) Vaccin tegen Pasteurella.
ES553425A0 (es) Perfeccionamientos en la fabricacion de conjugados de proteinas portadores de antigenos inmunogenicos para vacunas contra la malaria
DE3879968D1 (de) Malaria-impfstoff aus copolymerem protein.
KR890700356A (ko) 신규의 백신
KR890700358A (ko) 인체 종양관련 항원
BR8707549A (pt) Vacina contendo antigenos de carrapato
IL78869A0 (en) In vitro immunization of human splenocytes against tumor associated antigens
EP0467972A4 (en) Rickettsial antigens for vaccination and diagnosis
KR890701743A (ko) B형 간염 표면 항원 백신
PT88450A (pt) Antimalaria vaccines
IL81920A (en) Vaccines comprising an antigen and interferon-ypsilon and their preparation
DK375488D0 (da) Vaccine
KR890700604A (ko) 합성 항-카리에스 백신
IT8049346A0 (it) Composizione antigene relativo vaccino e procedimento di produzione
DK313687A (da) Fremgangsmaade til fremstilling af et antigen og vaccine indeholdende dette antigen
GB2200638B (en) Babesia divergens antigen and vaccine
IT8820888A0 (it) Peptidi di sintesi immunologicamente attivi per lapreparazione di vaccini antimalarici.
DK511687A (da) Farmaceutisk praeparat, samt fremstilling og anvendelse heraf

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970725